Clinical Hematology International最新文献_第10页

Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2). 白细胞介素-33 (IL-33)及其受体血清刺激2 (ST2)预测同种异体造血细胞移植后的免疫代谢并发症

Clinical Hematology International Pub Date : 2020-05-21 eCollection Date: 2020-09-01 DOI: 10.2991/chi.d.200506.002

Uttam K Rao, Brian G Engelhardt

引用次数: 2

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma. 自体干细胞移植治疗新诊断多发性骨髓瘤后的维持策略。

Clinical Hematology International Pub Date : 2020-05-20 eCollection Date: 2020-06-01 DOI: 10.2991/chi.d.200502.001

Sarah A Bird, Graham H Jackson, Charlotte Pawlyn

引用次数: 2

Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other. COVID-19 爆发期间的临床血液学实践：前所未有的挑战。

Clinical Hematology International Pub Date : 2020-05-20 eCollection Date: 2020-06-01 DOI: 10.2991/chi.d.200506.001

Mohamad Mohty, Arnon Nagler, Bipin Savani

引用次数: 0

Comparison of Conventional Cyclophosphamide versus Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation. 高危再生障碍性贫血患者行匹配相关供体移植常规环磷酰胺治疗与氟达拉滨治疗的比较

Clinical Hematology International Pub Date : 2020-05-18 eCollection Date: 2020-06-01 DOI: 10.2991/chi.d.200426.001

Raheel Iftikhar, Qamar Un Nisa Chaudhry, Tariq Mehmood Satti, Syed Kamran Mahmood, Tariq Ghafoor, Ghassan Umair Shamshad, Nighat Shahbaz, Mehreen Ali Khan, Tariq Azam Khattak, Jahanzeb Rehman, Muhammad Farhan, Saima Humayun, Humera Haq, Syeda Ammaara Anwaar Naqvi, Faiz Anwer, Humayoon Shafique Satti, Parvez Ahmed

{"title":"Comparison of Conventional Cyclophosphamide versus Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation.","authors":"Raheel Iftikhar, Qamar Un Nisa Chaudhry, Tariq Mehmood Satti, Syed Kamran Mahmood, Tariq Ghafoor, Ghassan Umair Shamshad, Nighat Shahbaz, Mehreen Ali Khan, Tariq Azam Khattak, Jahanzeb Rehman, Muhammad Farhan, Saima Humayun, Humera Haq, Syeda Ammaara Anwaar Naqvi, Faiz Anwer, Humayoon Shafique Satti, Parvez Ahmed","doi":"10.2991/chi.d.200426.001","DOIUrl":"https://doi.org/10.2991/chi.d.200426.001","url":null,"abstract":"Allogeneic stem cell transplant for high-risk aplastic anemia (AA) yields inferior results using conventional cyclophosphamide (CY)-based conditioning. The use of fludarabine (Flu)-based regimens has resulted in improved outcomes in high-risk patients. Limited data are available comparing these two conditioning regimens in such patients. We retrospectively analyzed 192 high-risk patients undergoing matched-related donor transplantation from July 2001 to December 2018. The median age was 19.5 (2-52) years. Patients were divided into 2 groups, Cy200 anti-thymocyte globulin (ATG)20 (Gp1 n = 79) or Flu120-150 Cy120-160 ATG20 (Gp2 n = 113). The risk of graft failure was significantly higher in Gp1, and the majority occurred in patients with >2 risk factors (p = 0.02). The incidence of grade II-IV acute graft versus host disease (GVHD) and chronic GVHD was not significantly different between the two groups. The overall survival (OS) of the study cohort was 81.3 %, disease-free survival (DFS) 76.6 % and GVHD-free relapse-free survival (GRFS) was 64.1%. DFS and GRFS were significantly higher in Gp2 as compared to Gp1: DFS 84.1% versus 68.4 % (p = 0.02), GRFS 77.9% versus 54.4% (p = 0.01), respectively. We conclude that Flu-based conditioning is associated with superior OS, DFS and GRFS as compared to the conventional Cy-based regimen in high-risk AA.","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"2 2","pages":"82-91"},"PeriodicalIF":0.0,"publicationDate":"2020-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e5/10/CHI-2-2-82.PMC8432348.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39477347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better. 硼替佐米、来那度胺和地塞米松作为多发性骨髓瘤自体移植前的诱导疗法：越多越好

Clinical Hematology International Pub Date : 2020-05-18 eCollection Date: 2020-06-01 DOI: 10.2991/chi.d.200507.001

Mohamad Mohty, Florent Malard, Ali Bazarbachi

引用次数: 0

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features. R-CHOP与剂量调整R-EPOCH治疗高风险弥漫性大b细胞淋巴瘤的成本分析

Clinical Hematology International Pub Date : 2020-04-23 eCollection Date: 2020-09-01 DOI: 10.2991/chi.d.200410.001

Bhagirathbhai Dholaria, Yenny Alejandra Moreno Vanegas, Nancy Diehl, Aaron C Spaulding, Sue Visscher, Han W Tun, Sikander Ailawadhi, Prakash Vishnu

{"title":"Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features.","authors":"Bhagirathbhai Dholaria, Yenny Alejandra Moreno Vanegas, Nancy Diehl, Aaron C Spaulding, Sue Visscher, Han W Tun, Sikander Ailawadhi, Prakash Vishnu","doi":"10.2991/chi.d.200410.001","DOIUrl":"https://doi.org/10.2991/chi.d.200410.001","url":null,"abstract":"Dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA.R-EPOCH) is used for upfront treatment of high-risk diffuse large B cell lymphoma (DLBCL). In this study, we compared the outcomes in patients with high-risk DLBCL who received frontline rituximab, cycophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) or DA.R-EPOCH immunochemotherapy. Outcomes and treatment-related cost were analyzed. DLBCL with one of the following features were included in the study: MYC ± BCL2 or BCL6 rearrangement by FISH or MYC overexpression by immunohistochemistry, Ki67 index ≥ 80% or nongerminal center immunophenotype, tumor measuring ≥5 cm and NCCN- IPI score ≥4. A total of 80 patients were treated with R-CHOP (n = 52, 65%) or DA.R-EPOCH (n = 28, 35%), with a median follow-up of 11.2 months (range: 0.7-151.3 months). The hazard ratios (HRs) for progression-free survival and overall survival were 0.79 [95% confidence interval (CI) 0.28%-2.29%, p = 0.67] and 0.86 (95% CI 0.26%-2.78%, p = 0.80), respectively for DA.R-EPOCH compared to R-CHOP. The total mean cost was USD106,940 ± USD39,351 and USD58,509 ± 24,588 for DA.R-EPOCH and R-CHOP respectively (p < 0.001). In our analysis, DA.R-EPOCH resulted comparable clinical outcomes and increased treatment-related expenses compared to R-CHOP in high-risk DLBCL.","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"2 3","pages":"117-124"},"PeriodicalIF":0.0,"publicationDate":"2020-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/76/df/CHI-2-3-117.PMC8432333.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39476335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Haploidentical Hematopoietic Stem Cell Transplantation Followed by 'Post-Cyclophosphamide': The Future of Allogeneic Stem Cell Transplant. 环磷酰胺后 "的同种异体造血干细胞移植：同种异体干细胞移植的未来。

Clinical Hematology International Pub Date : 2020-04-19 eCollection Date: 2020-06-01 DOI: 10.2991/chi.d.200405.001

Samuel Cytryn, Maher Abdul-Hay

{"title":"Haploidentical Hematopoietic Stem Cell Transplantation Followed by 'Post-Cyclophosphamide': The Future of Allogeneic Stem Cell Transplant.","authors":"Samuel Cytryn, Maher Abdul-Hay","doi":"10.2991/chi.d.200405.001","DOIUrl":"10.2991/chi.d.200405.001","url":null,"abstract":"Allogeneic hematopoietic cell transplant (Allo-HCT) is a potentially curative therapy for many malignant and nonmalignant hematological diseases. However, a suitable human leukocyte antigens (HLAs)-matched donor may not be available when the patient is in urgent need of a stem cell transplant. This challenge has been ameliorated to a large extent by the introduction of haploidentical donors. This type of donor shares one HLA haplotype with the recipient. Therefore, a patient's full sibling has a 50% chance of being haploidentical and a patient's biologic parents and children will all be haploidentical, thus providing an immediately accessible, motivated donor for almost every recipient. Haploidentical transplants previously incurred prohibitively poor outcomes, preventing their widespread use. However, several recent advances have dramatically improved the results, making them a more viable donor source. In this review, we discuss different types of donors used for Allo-HCT with a particular focus on the use of haploidentical donors and their future potential.","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"2 2","pages":"49-58"},"PeriodicalIF":0.0,"publicationDate":"2020-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/74/CHI-2-2-49.PMC8432344.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39477343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The CD34⁺ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors. CD34+细胞剂量对兄弟姐妹外周血干细胞造血干细胞移植的影响

Clinical Hematology International Pub Date : 2020-03-04 eCollection Date: 2020-06-01 DOI: 10.2991/chi.d.200221.001

M Remberger, B Grønvold, M Ali, J Mattsson, T Egeland, K U Lundin, A Myhre, I Abrahamsen, D Heldal, I Dybedal, G E Tjønnfjord, T Gedde-Dahl, Y Fløisand

{"title":"The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors.","authors":"M Remberger, B Grønvold, M Ali, J Mattsson, T Egeland, K U Lundin, A Myhre, I Abrahamsen, D Heldal, I Dybedal, G E Tjønnfjord, T Gedde-Dahl, Y Fløisand","doi":"10.2991/chi.d.200221.001","DOIUrl":"https://doi.org/10.2991/chi.d.200221.001","url":null,"abstract":"The effect of CD34+ cell dose in allogeneic hematopoietic stem cell transplantation (HSCT) on overall survival (OS) and incidence of acute and chronic graft-versus-host disease (GvHD) has not been established and few studies have been performed. Our single center analysis included 189 patients with hematological malignancies who received peripheral blood stem cell (PBSC) grafts from sibling donors. Myeloablative conditioning was used in 88 cases and 101 received reduced intensity conditioning. The median CD34+ cell dose was 5.6 × 106/kg (0.6-17.0). In the multivariate analysis, a CD34 cell dose of 6-7 × 106/kg was associated with better OS and lower transplant-related mortality (TRM), while a dose of <5 × 106/kg led to increased relapse and reduced chronic GVHD (cGVHD). A high CD34 cell-dose (>6.5 × 106/kg) correlated with less acute GVHD (aGVHD) II-IV. We conclude that the CD34 cell dose has an impact on the outcome of HSCT from sibling donor PBSCs.","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"2 2","pages":"74-81"},"PeriodicalIF":0.0,"publicationDate":"2020-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/3b/CHI-2-2-74.PMC8432346.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39477346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia. 针对复发或难治性急性髓性白血病的定时序贯挽救性化疗。

Clinical Hematology International Pub Date : 2020-03-01 Epub Date: 2019-12-09 DOI: 10.2991/chi.d.191128.001

Bogdan Popescu, Sheenu Sheela, Julie Thompson, Sophia Grasmeder, Therese Intrater, Christin B DeStefano, Christopher S Hourigan, Catherine Lai

{"title":"Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia.","authors":"Bogdan Popescu, Sheenu Sheela, Julie Thompson, Sophia Grasmeder, Therese Intrater, Christin B DeStefano, Christopher S Hourigan, Catherine Lai","doi":"10.2991/chi.d.191128.001","DOIUrl":"10.2991/chi.d.191128.001","url":null,"abstract":"Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may have particular utility for that indication. We report here a series of ten such adult patients treated sequentially at a single center with EMA (cytarabine 500 mg/m2/day as continuous infusion on days 1-3 and days 8-10, mitoxantrone 12 mg/m2/day on days 1-3, and etoposide 200 mg/m2/day as continuous infusion on days 8-10). The overall complete remission rate was 40% (including 3 of 4 of those with relapsed disease) but use of this regimen was associated with prolonged cytopenia and a high rate of infectious adverse events. Even with the availability of modern infectious prophylaxis and therapies, the EMA regimen is likely best reserved for those with relapsed disease treated with curative intent prior to an allogeneic hematopoietic cell transplant.","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"2 1","pages":"27-31"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/8a/CHI-2-1-27.PMC7079712.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37752402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Repeat Endoscopy Affects Patient Management in Gastrointestinal Graft-Versus-Host Disease. 重复内镜检查对胃肠道移植物抗宿主病患者管理的影响

Clinical Hematology International Pub Date : 2020-02-27 eCollection Date: 2020-06-01 DOI: 10.2991/chi.d.200220.001

Ehsan Shabbir, Umar Farooq, Burhan Yanes, Margarida Magalhaes-Silverman

{"title":"Repeat Endoscopy Affects Patient Management in Gastrointestinal Graft-Versus-Host Disease.","authors":"Ehsan Shabbir, Umar Farooq, Burhan Yanes, Margarida Magalhaes-Silverman","doi":"10.2991/chi.d.200220.001","DOIUrl":"https://doi.org/10.2991/chi.d.200220.001","url":null,"abstract":"Graft versus host disease (GVHD) of the gut is associated with significant morbidity and mortality after allogeneic hematopoietic cell transplant (allo-HCT). No guidelines exist regarding repeat endoscopy after failure of first-line treatment with steroids. We aimed to study if repeat endoscopic biopsy can be helpful in these patients to guide treatment decisions. We retrospectively reviewed medical records of all patients who underwent repeat endoscopy for clinical suspicion of gastrointestinal (GI) GVHD after allo-HCT. Of the 318 patients, 24 underwent endoscopy twice after allo-HCT. At first endoscopy, 20 patients (80%) showed abnormal findings: 16 with GVHD alone, 1 with GVHD plus cytomegalovirus (CMV), and 3 with GVHD plus infectious colitis. On repeat endoscopy in these 20 patients with GVHD, 6 showed improvement leading to de-escalation of therapy, 8 showed worsening of GVHD including detection of CMV in 2 patients, and 2 had no histological changes. One patient with simultaneous GVHD and CMV diagnosed on first biopsy, displayed significant improvement leading to de-escalation of therapy. Three patients with GVHD along with infectious colitis on biopsy subsequently showed improvement on repeat biopsy leading to de-escalation of therapy. Among 4 patients with normal findings on first endoscopy, 3 had GVHD and 1 had epstein-barrvirus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) on repeat procedures. This study supports the usefulness of repeat endoscopy in persistently symptomatic patients when there is no improvement after the initial treatment based on the results of the first endoscopy. Repeat endoscopy may guide therapy without significant complications.","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"2 2","pages":"69-73"},"PeriodicalIF":0.0,"publicationDate":"2020-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/e1/CHI-2-2-69.PMC8432351.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39477344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4